Thyroid Eye Disease clinical trials

Explore recruiting thyroid eye disease clinical trials.

Recruiting thyroid eye disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thyroid Eye Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Spain, Germany, France, Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease

Estonia, Czechia, Germany, Spain, Greece, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

VRDN-003-302: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)

Germany, Spain, Hungary, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

VRDN-003-301: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)

Hungary, Spain, Poland, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)

Spain, Hungary, Poland, France, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Thyroid Eye Disease trials by city

Thyroid Eye Disease in Toronto Thyroid Eye Disease in Vancouver Thyroid Eye Disease in Montreal Thyroid Eye Disease in Calgary Thyroid Eye Disease in Edmonton Thyroid Eye Disease in Ottawa Thyroid Eye Disease in Winnipeg Thyroid Eye Disease in Quebec City Thyroid Eye Disease in Hamilton Thyroid Eye Disease in Kitchener Thyroid Eye Disease in London Thyroid Eye Disease in Halifax Thyroid Eye Disease in New York Thyroid Eye Disease in Los Angeles Thyroid Eye Disease in Chicago Thyroid Eye Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease